Predictive Intelligence: Melasma Face Cream

Formulation Analysis & Clinical Roadmap Dashboard

Region: India (CDSCO/AYUSH Compliant)

Active Ingredients

5 Key Leads

Safety Profile

Moderate-High

Clinical Evidence

Human-Level

Primary Target

Tyrosinase

Executive Summary

W/O Emulsion Base (61% Water)

Silymarin: Strong Human Melasma Evidence

Aloe Vera: 12-week Melanin Index Reduction

TiO2: 1% Physical UV Protection

Regulatory Alert

Product must be positioned as Cosmetic/AYUSH-linked. Claims like "Treats Melasma" or "Cures Hyperpigmentation" are high-risk and non-compliant with CDSCO Cosmetics Rules.

Target Mechanism Priority

Tyrosinase Inhibition 95%

ROS Scavenging 88%

Compound	Conc.	Mechanism
Aloe Vera Extract	2.0%	Depigmenting/Anti-inflammatory
Silymarin	0.1-0.2%	Tyrosinase Inhibitor
Moringa Oil	2.0%	Antioxidant/Emollient

Patient Stratification

Benefit

Adults (18-65) with mild/moderate melasma seeking botanical alternatives.

Avoid

Patients with active eczema or Asteraceae allergy.

8-Week Monitoring Roadmap

Standardized monitoring plan for efficacy and safety.

Week 1-2

Skin Tolerance

Check for burning or redness.

Week 8

Final Endpoint

Global improvement check.

Clinician-Facing Summary

This formulation leverages botanical tyrosinase inhibitors with human clinical validation for Melasma. Profile is emollient-heavy, ideal for dry skin. Key risks include contact dermatitis and the need for secondary SPF support.